These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9352986)

  • 21. Economic benefits of amlodipine treatment in patients with coronary artery disease.
    Casciano R; Doyle JJ; Chen J; Arikian S; Casciano J; Kugel H; Arocho R
    Pharmacoeconomics; 2002; 20(8):553-63. PubMed ID: 12109920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
    Teo KK; Burton JR; Buller C; Plante S; Yokoyama S; Montague TJ
    Can J Cardiol; 1997 Jun; 13(6):591-9. PubMed ID: 9215232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial.
    Tulenko TN; Brown J; Laury-Kleintop L; Khan M; Walter MF; Mason RP
    J Cardiovasc Pharmacol; 1999; 33 Suppl 2():S17-22. PubMed ID: 10071259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Circadian rhythm in the clinical course of cardiovascular diseases. Clinical experience using Norvasc (amlodipine) in the treatment of patients with ischemic heart disease and arterial hypertension].
    Oganov RG; Gratsianskiĭ NA; Mazur NA; Lazebnik LB; Belousov IuB; Sidorenko BA; Ol'binskaia LI; Vertkin AL; Shevchenko OP; Karpov IuA
    Kardiologiia; 1992 May; 32(5):99-112. PubMed ID: 1405279
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries.
    Ouyang P; Tardif JC; Herrington DM; Stewart KJ; Thompson PD; Walsh MN; Bennett SK; Heldman AW; Tayback MA; Wang NY;
    Atherosclerosis; 2006 Dec; 189(2):375-86. PubMed ID: 16442114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DUAAL: atorvastatin provided an unexpectedly potent heart benefit in patients with chronic stable angina.
    Cardiovasc J Afr; 2008; 19(3):174. PubMed ID: 18568187
    [No Abstract]   [Full Text] [Related]  

  • 29. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
    J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of amlodipine on transient myocardial ischaemia in patients with a severe coronary condition treated with a beta-blocker. Amlor-Holter Study Investigators.
    Madjlessi-Simon T; Fillette F; Mary-Krause M; Lechat P; Jaillon P
    Eur Heart J; 1995 Dec; 16(12):1780-8. PubMed ID: 8682007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
    Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Hu B; Uno K; Kataoka Y; Herrman JP; Merkely B; Borgman M; Nissen SE
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):55-65. PubMed ID: 26385396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden.
    Doyle JJ; McGuire A; Arocho R; Arikian S; Casciano J; Svangren P; Casciano R; Kim R; Kugel H
    Int J Clin Pract; 2002 Mar; 56(2):76-81. PubMed ID: 11926709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis.
    Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP
    JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.